Mollard, Alexis,Warner, Steven L.,Flynn, Gary A.,Vankayalapati, Hariprasad,Bearss, David J.
申请号：
AU2018256624
公开号：
AU2018256624A1
申请日:
2018.11.02
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
C: Users kzh App.Data Local TempinMailX i 0015 a U i Abs t - 355 18948.DOCX-1/l 1/2018 Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): Re (R5 N ±N 1R2 (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, 1 2 3 4 5 6 7 8 wherein R , R , R', R4, R , R', R', R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. WO 2014/151871 PCT/US2014/026595 5 1 Cn U) C 0.8 x - 0.6 - cj0.4 >； 0.2 0 No Drug No. 7 No.4 No. 10 No.20 No. 12 No. 11 No.23 HEPG2 cells treated with 1 pM compound *~ 1 e M No.4 0.6 - No.12 DMSO 3uM luM .3uM
